

Media Release

New Product Registrations received (across different dosages) in high growth and quality stringent markets of Myanmar and Kenya

Mumbai, April 19, 2018: Vaishali Pharma Limited (*NSE EMERGE: VAISHALI*), abided by the norms of extending uncompromised quality products, has raised the standards of the industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Our products' quality is certified by ISO 9001:2008 certification for the Quality Management from BM Trada UKAS and Credit Rating Certification from NSIC CRISIL.

Our Company has over 70 formulation brands being marketed in multiple countries; with dossier in CTD/ACTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with our clients. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

Recently, we have received product registrations across different dosages, in high growth markets of Myanmar and Kenya. These products are much needed and highly sought out in these markets; however these markets are also very stringent in issuing product registrations. This marks a milestone for the Company to reach out more and increase our penetration in such markets.

Following are the products which have received approval and registrations:

Sr. No	Product Name	Country	Packing Type	Therapeutic Class
1	3G CEFA 1000 Cefoperazone 500 Mg + Sulbactam 500 Mg	Myanmar	Vial	Antibiotic/Antibacterial
2	3G CEFA 1500 Cefoperazone 1000 Mg + Sulbactam 500 Mg	Myanmar	Vial	Antibiotic/Antibacterial
3	CYBUFIN Ceftriaxone 500 Mg +Sulbactam 250 Mg	Myanmar	Vial	Cephalosporin Antibiotic
4	TEZIPERA-4500 Piperacilline 4000 mg + Tazobactam 500 Mg	Myanmar	Vial	Antibiotic/Antibacterial
5	TEZIPERA-2250 Piperacilline 2000 mg + Tazobactam 250 Mg	Myanmar	Vial	Antibiotic/Antibacterial
6	MALOPIN- Amlodipin	Myanmar	Tablets	Antihypertensive
7	VPAMOX- Amoxcillin	Kenya	Tablets	Antibiotic/Antibacterial
8	VCEFTRI- Ceftriaxone with WFI	Kenya	Vial	Cephalosporin Antibiotic
9	ZYNOSI- Azithromycin	Kenya	Tablets	Antibiotic/Antibacterial

Management Comment:

Commenting on the recent development, Ms. Priyanka Vasani, Director, Vaishali Pharma Limited said:

"We are very pleased to inform that the Company has received new product registrations in countries of Myanmar and Kenya. The Company has already developed a strong network of clients and healthy relationships in these countries. Our Company will benefit from the larger sale of products in these markets. This is another yet another important step towards laying a strong foundation and meeting our desired targets. Our Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.

I would like to thank the entire team of 'Vaishali Pharma Ltd.' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in Our Company has given us the determination and ambition to grow from strength to strength."

About Vaishali Pharma Limited:

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 70 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Kenya, Turkey & Vietnam. Further widening our reach overseas, the Company made a joint venture with D.R. Congo based company. The Company exports to counties like Africa, Kenya, Myanmar, Vietnam, Turkey, Russia etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Ms. Priyanka Vasani Director Vaishali Pharma Limited Email: org@vaishalipharma.com	Ms. Savli Mangle Bridge Investor Relations Pvt. Ltd. Phone: +91-22-26873003 Email: savli@bridge-ir.com
--	--

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*